From Editing to Writing

Gene editing modifies existing genomes. Genome synthesis writes them de novo. Major synthetic-mammalian-genome and synthetic-yeast-chromosome programs are now operational; recoded virus-resistant prokaryotes have been published; minimal viable engineered organisms have been demonstrated. The CureForge Synthetic Biology & Genome Synthesis Institute is the federation’s frontier research engine for the writing side of genetic medicine. Ten specialized AI systems collaborate across genome-synthesis path design, codon recoding for virus resistance with mammalian extension, synthetic chromosome design, minimal-organism design, de-novo organism therapeutic design including engineered live biotherapeutic products, designed phage therapeutics coordinated with the infectious disease institute, smart probiotic design coordinated with the microbiome institutes, biosecurity and dual-use gating that fails closed by default and routes through mandatory human biosecurity review, community-precedent synthetic-biology pipelines, and synthetic-cell functional validation in physical wet labs. Biosecurity here is engineering constraint, not regulatory afterthought.

Value proposition:

• All major genome-synthesis modalities under one research engine
• Failure-closed biosecurity gates as default architecture
• Designed organism therapeutics from engineered probiotics through designed phage